Funding rounds · Week 37 · 13 September 2026
weekly · 7d window · SEC Form D
All funding rounds editions →$43.5m
$43.5m of $50.6m target
Airway Therapeutics develops biologic medicines for respiratory and inflammatory diseases. Its lead work uses a recombinant form of surfactant protein D to address lung injury and impaired immune defence.
weekly · 7d window · SEC Form D
All funding rounds editions →Get early signals on the websites, apps, repositories and startups gaining momentum. Join the list for Risefinder email briefings.
Be first to receive the briefing.